Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study).
Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study).
复制标题
DOI：
10.1186/1745-6215-9-8
复制
发表时间：
2008-02-25
期刊：
影响因子：
2.5
通讯作者：
Foley, Claire E.
中科院分区：
文献类型：
--
作者：
Crossman, David C.;Morton, Allison C.;Gunn, Julian P.;Greenwood, John P.;Hall, Alistair S.;Fox, Keith Aa;Lucking, Andrew J.;Flather, Marcus D.;Lees, Belinda;Foley, Claire E.
急性冠状动脉综合征占英国死亡人数的15%，患者因未来并发症和死亡而再次入院的风险仍然很大。在病理学上，动脉粥样硬化的潜在过程是由炎症机制驱动的，这些炎症机制在ACS患者中被激活。以前的研究已经调查了炎症标志物在这一过程中的作用，包括白细胞介素1（IL-1）和C反应蛋白（CRP）。临床前研究表明，IL-1可能是ACS的主要驱动因素，天然存在的白细胞介素-1受体拮抗剂（IL-1 ra）可能抑制动脉粥样硬化过程。本研究将探讨IL-1 ra对人类炎症标志物的影响。英国三个中心计划招募186名非ST段抬高型心肌梗死患者接受白细胞介素-1受体拮抗剂（Anakinra）或匹配的安慰剂。患者将在14天内接受每日皮下注射研究药物或安慰剂。主要结果是前7天的高敏C反应蛋白（CRP）曲线下面积。MRC-ILA-HEART研究是一项概念验证临床试验，旨在研究IL-1 ra对非ST段抬高心肌梗死患者炎症标志物的影响。希望这将为急性冠脉综合征患者的“抗炎”策略提供新的令人兴奋的信息。ISRCTN89369318
Acute Coronary Syndromes account for 15% of deaths in the UK, and patients remain at significant risk of re-admission for future complications and death. Pathologically the underlying process of atherosclerosis is driven by inflammatory mechanisms, which are activated in ACS patients. Previous studies have investigated the role of inflammatory markers in this process, including interleukin 1 (IL-1) and C Reactive Protein (CRP). Pre-clinical studies indicate that IL-1 may be a primary driver of ACS and that the naturally occurring interleukin-1 receptor antagonist (IL-1ra) may inhibit the atherosclerotic process. This study will investigate the effects of IL-1ra on inflammatory markers in man. Three centres in the UK are planning to recruit 186 Non-ST elevation myocardial infarction patients to receive either interleukin-1 receptor antagonist (Anakinra) or matching placebo. Patients will receive a daily subcutaneous injection of either study drug or placebo over a 14 day period. The primary outcome is area under the curve of high sensitivity C-Reactive Protein (CRP) over the first 7 days. The MRC-ILA-HEART Study is a proof of concept clinical trial investigating the effects of IL-1ra upon markers of inflammation in patients with Non-ST elevation myocardial infarction. It is hoped this will provide new and exciting information in relation to an "anti-inflammatory" strategy for patients with acute coronary syndrome. ISRCTN89369318
登录
查看更多内容
影响因子：
37.8
作者：
Francis, SE;Camp, NJ;Crossman, DC
通讯作者：
Crossman, DC
影响因子：
37.8
作者：
Lindahl, B;Venge, P;Wallentin, L
通讯作者：
Wallentin, L
影响因子：
120.7
作者：
ANTMAN, EM;GRUDZIEN, C;SACKS, DB
通讯作者：
SACKS, DB
影响因子：
3.8
作者：
Berger, P;McConnell, JP;Duff, GW
通讯作者：
Duff, GW
影响因子：
37.8
作者：
Liuzzo, G;Buffon, A;Maseri, A
通讯作者：
Maseri, A